Aileron Therapeutics' Phase 1b trial shows LTI-03 improved biomarkers and reduced SPD levels, indicating the potential to ...
Accumulation of extracellular matrix (ECM) in liver fibrosis is associated with changes in protein abundance and composition depending upon etiology of the underlying liver disease. Current efforts to ...
(RTTNews) - Aileron Therapeutics, Inc. (ALRN), Wednesday announced positive topline data from the cohort 2 of Phase 1b study evaluating LTI-03 in patients with idiopathic pulmonary fibrosis (IPF).
The topline data showed ISM001-055 to have improved the forced vital capacity (FVC) of IPF patients studied 12 weeks after ...
Brilaroxazine is generally well tolerated to date in patients with acute and stable schizophrenia – – Topline data from 1-year open-label extension (OLE) trial now expected in December 2024 – ...
The National Prion Disease Pathology Surveillance Center (NPDPSC) is the only Center of its kind in the U.S., which coordinates autopsies and neuropathologic examinations of suspected prion disease ...
Surrozen, Inc. ('Surrozen” or the 'Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today announced ...
TCGFB, a private biotech founded by healthcare VC The Column Group, is tapping California biotech Surrozen to discover ...
Research collaboration to leverage Surrozen's antibody research capabilities and expertise to discover a potential first in class <a target=_blank ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback